Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Colliers International
CIGI
$5.18B
| $49.6M | 0.06% |
877,900
+42,800
| +5% | +$2.22M |
|
|
RP
377
DELISTED
RealPage, Inc.
RP
| $49.6M | 0.06% |
1,378,538
+586,144
| +74% | +$20.9M |
|
378
Papa John's
PZZA
$794M
| $49.4M | 0.06% |
688,668
-82,100
| -11% | -$6.49M |
|
|
VR
379
DELISTED
Validus Hold Ltd
VR
| $49.4M | 0.06% |
950,569
+630,835
| +197% | +$34M |
|
380
Air Products & Chemicals
APD
$68.1B
| $49M | 0.06% |
342,500
-50,100
| -13% | -$7.12M |
|
381
Brixmor Property Group
BRX
$9.11B
| $48.9M | 0.06% |
2,732,600
-960,200
| -26% | -$18.6M |
|
382
Itron
ITRI
$4.48B
| $48.8M | 0.06% |
719,661
+198,700
| +38% | +$13M |
|
383
UGI
UGI
$7.49B
| $48.7M | 0.06% |
1,005,950
-243,500
| -19% | -$12.1M |
|
384
Black Hills Corp
BKH
$5.6B
| $48.6M | 0.06% |
720,800
+190,500
| +36% | +$13.1M |
|
|
KEM
385
DELISTED
KEMET Corporation
KEM
| $48.5M | 0.06% |
3,789,099
+1,418,000
| +60% | +$18M |
|
|
NVMI
386
Nova
NVMI
$13B
| $48.5M | 0.06% |
2,194,700
+26,100
| +1% | +$581K |
|
387
Regency Centers
REG
$13.9B
| $48.5M | 0.06% |
773,945
+187,200
| +32% | +$11.8M |
|
388
Caesars Entertainment
CZR
$6.04B
| $48.4M | 0.06% |
2,419,521
+1,624,021
| +204% | +$32.5M |
|
389
Quest Diagnostics
DGX
$26.3B
| $48.4M | 0.06% |
435,300
-68,400
| -14% | -$7.23M |
|
390
TC Energy
TRP
$66.6B
| $48M | 0.06% |
1,007,300
-213,803
| -18% | -$10M |
|
391
Evertec
EVTC
$1.81B
| $47.8M | 0.06% |
2,763,400
-144,300
| -5% | -$2.36M |
|
392
Banco de Chile
BCH
$20.5B
| $47.7M | 0.06% |
1,927,236
-56,903
| -3% | -$1.37M |
|
|
WNS
393
DELISTED
WNS Holdings
WNS
| $47.7M | 0.06% |
1,387,400
-20,823
| -1% | -$663K |
|
|
AUO
394
DELISTED
AU Optronics Corp
AUO
| $47.6M | 0.06% |
10,440,384
+1,929,700
| +23% | +$7.75M |
|
395
Etsy
ETSY
$7.26B
| $47.6M | 0.06% |
3,170,300
-738,800
| -19% | -$9.17M |
|
396
Owens Corning
OC
$12.3B
| $47.6M | 0.06% |
710,600
-459,200
| -39% | -$28.8M |
|
|
CDK
397
DELISTED
CDK Global, Inc.
CDK
| $47.3M | 0.06% |
762,600
+496,700
| +187% | +$31.2M |
|
398
ConocoPhillips
COP
$151B
| $47M | 0.06% |
1,069,813
-1,892,000
| -64% | -$88.2M |
|
399
Illumina
ILMN
$28.9B
| $47M | 0.06% |
+278,504
| New | +$48.2M |
|
|
DNB
400
DELISTED
Dun & Bradstreet
DNB
| $46.9M | 0.06% |
433,958
+256,458
| +144% | +$27.5M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.